YonaLink and TrialJectory (TIME’s 100 Best Inventions of 2020) win the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation Grant.
JERUSALEM, Sept. 23, 2021 — Following a recent announcement by the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation, YonaLink and TrialJectory have won a $1 million grant to develop a platform to enroll diverse patients from various sites in clinical trials by automating the clinical trial value chain, from patient selection to data management. This grant, split between the two companies, is part of a $6 million allocation for six projects between partnered U.S. and Israeli companies.
We are proud to support the development of technology capable of lowering the barriers for conducting clinical trials in diverse sites and expanding patient enrollment. The BIRD Foundation will continue to support innovative projects that develop solutions for present challenges.
The joint project redesigns the clinical trial process by shifting the focus from site-oriented to patient-oriented. Using Yonalink’s and TrialJectory’s proprietary technologies, the companies automate the complex process of conducting clinical trials, overcoming cost, time, and resource constraints that bar most medical centers and patients from participating in trials. Together, screening potential patients and connecting them to the site will eliminate the manual work involved in data management and patient enrollment. As a result, this will increase enrollment and decrease the cost and time needed to conduct clinical trials, bringing new therapies to market faster than ever before.
This grant that has been awarded to New Jersey-based TrialJectory and YonaLink in Jerusalem represents the kind of tech innovation that can and will save lives. By speeding up the process for connecting the right patients for clinical trials and managing the vital data from those trials, this BIRD Foundation grant represents not only our best technology but our best ideals.
TrialJectory is a patient-first, digital health company with a mission to democratize access to advanced cancer treatment. With more than 35,000 cancer patients and a monthly community growth rate of 15 percent, the company has been recognized by TIME as one of “The 100 Best Inventions of 2020” and named an honoree in the AI and data category for Fast Company’s “2021 World-Changing Ideas Awards.”
TrialJectory uses artificial intelligence (AI) to match and empower cancer patients to get more involved in decisions about their treatment. The only offering of its kind, TrialJectory provides direct access to cancer patients and comprehensive, proprietary data and insights about the patient, including medical information with genetic and biomarker results, demographic details, and insight into the decisions they made about their treatment. TrialJectory also delivers quantitative data about patient motivators and barriers when it comes to clinical trial participation. This level of visibility into the cancer patient’s experience can directly impact the evolution of oncology research, improve accessibility and diversity.
In December 2013, I was diagnosed with malignant melanoma. After participating in three clinical trials, I quickly learned that the way in which patients gain access to advanced treatments through clinical trials is completely broken. Through this grant and our partnership with YonaLink, we will be able to continue with our mission and drive the patient-first approach to the way clinical trials are running.
YonaLink’s AI-driven clinical trial data management platform adds real-time streaming data to the improved TrialJectory clinical trial process. This saves clinical trial sponsors more than 30 percent on the cost, and months in data management, cleansing, and analysis.
Our platform guarantees secure, error-free, live data-streaming that enhances productive collaboration between health care providers and clinical trial researchers. The YonaLink model is a much-needed cost and time effective solution that propels clinical research by expanding diversity and enrollment in trials, and enables participation of smaller medical centers, while also ensuring patient safety by eliminating manual data capture, monitoring, and conversion.
The combination of two innovative technologies, YonaLink and TrialJectory, enables this project’s novel approach to come to life. These technologies function as a joint platform that allows the paradigm shift to redesign clinical trials as patient-centric. While the TrialJectory technology matches patients and supports patients’ application, wherever they are, to relevant clinical trials, by reducing the enrollment period by 20 percent; the YonaLink system provides the technological means permitting trial sponsors to save on traditional trial costs and reduce the analysis time by months. The result is the diversification of clinical trial populations and clinical trial sites, answering the pressing market need.
YonaLink is a technology company that is bringing next-generation, innovative solutions to the clinical trial market. The company’s data-driven SaaS platform converts and migrates CDISC/SDTM formatted data from electronic patient health records (EHR) in medical centers to clinical research databases (EDC). This data collection process guarantees secure, error-free, real-time access to patient information, enhancing collaboration between healthcare providers and clinical trial researchers. The YonaLink model is a cost and time-saving offering that propels clinical research into the modern era. It expands patient diversity and enrollment in clinical trials while also ensuring patient safety by eliminating manual data capture, monitoring, and conversion. For more information, visit yonalink.com and follow us on LinkedIn and Twitter.
TrialJectory is a patient-first digital health company with a mission to democratize access to advanced cancer treatment. Recognized by TIME as one of “The 100 Best Inventions of 2020,” TrialJectory uses artificial intelligence (AI) to empower patients to own their cancer journey and analyzes its global patient community’s real-world data to empower cancer patients to make the most informed decisions about their care. For more information, please visit www.trialjectory.com.